Acorda Therapeutics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Acorda Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACOR, but not buy additional shares or sell existing shares.
View analyst ratings for Acorda Therapeutics or view top-rated stocks.

Wall Street analysts have given Acorda Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acorda Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Acorda Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,070,000 shares, an increase of 40.6% from the February 28th total of 761,100 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 11.5% of the company's stock are short sold.
View Acorda Therapeutics' Short Interest.

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Acorda Therapeutics.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its earnings results on Wednesday, March, 3rd. The biopharmaceutical company reported ($2.50) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.57) by $0.07. The biopharmaceutical company earned $38.16 million during the quarter, compared to analysts' expectations of $34 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 8.60% and a net margin of 29.71%.
View Acorda Therapeutics' earnings history.

Acorda Therapeutics' stock was trading at $6.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACOR shares have decreased by 30.9% and is now trading at $4.19.
View which stocks have been most impacted by COVID-19.

Shares of Acorda Therapeutics reverse split on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 31st 2020. An investor that had 100 shares of Acorda Therapeutics stock prior to the reverse split would have 17 shares after the split.

2 brokers have issued 1-year target prices for Acorda Therapeutics' shares. Their forecasts range from $6.00 to $35.00. On average, they anticipate Acorda Therapeutics' stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 464.8% from the stock's current price.
View analysts' price targets for Acorda Therapeutics or view top-rated stocks among Wall Street analysts.

39 employees have rated Acorda Therapeutics CEO Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among Acorda Therapeutics' employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ACOR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACOR stock can currently be purchased for approximately $4.19.

Acorda Therapeutics has a market capitalization of $39.76 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($11.94) on an earnings per share basis.

Acorda Therapeutics employs 167 workers across the globe.

The official website for Acorda Therapeutics is www.acorda.com.

Acorda Therapeutics is headquartered at 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502.

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.